Member Info for PJT12

the problem with the medical profession is it really is soooooooo slow and, in the case of too many staff in the nhs (and presumably elsewhere) in the present climate the job's seen as an ****-covering box-ticking exercise (in this case, the psa test will do), doing just enough to achieve that. beyond that? not my concern, guv.

The likely sales are likely already built into the price; what isn't is the really quick speed at which the reimbursement code was awarded. Next up most likely, according to their previous reports, colon cancer.

28-Sep-23 12:59:22 58.00 500,000 Buy* 55.20 58.00 290.00k

At least the MD has the decency to empathise through the letter. Many wouldn't have bothered.

You do all know that Timster's surname is Wallace, hmm?............TW? Just saying.

"Her deep knowledge of how the worlds of technology and content combine to drive each other forward perfectly aligns with our Digital Vending Machine strategy".

I think that's the key sentence here. "Content" is King and ours needs to be top drawer in order to sell it on what is already an industry leading platform.........

The falling £ won't can only add to profits through the year too.

Until global governments present a genuinely united front on renewables - rather than what is often coming across as lip-service in many cases - then the uncertainty and resulting lack of real commitment behind potential future investment will continue. People and companies will also continue pointing at India and China's emissions, thus taking a "what's the point of us cutting our noses off....?" line. A move towards renewables is desirable but the timescale does not allow for a transition away from the above concerns, imo.

RBC cuts Melrose Industries to 'sector perform' (outperform) - price target 540 (525) pence

A good reason to fill your boots based upon many a broker's "forecast".

Cheers, Hanoi. Worth knowing.

Twice now, AI (Bing) has provided me answers with outdated "thinking". Firstly, it gave me the PM of Malaysia as being a bloke who's no longer in position and secondly, in response to my question, Is AVA6000 likely to succeed?, I got the following reply (Spot the mistake!)

AVA6000 is a novel precision medicine that is designed to target the tumor microenvironment via fibroblast activation protein (FAP) mediated cleavage1. It is based on a proprietary technology called pre|CISION™, which can generate chemotherapy prodrugs that are only activated in the presence of FAP2. FAP is overexpressed on the surface of activated fibroblastic cells, which are abundant in the supporting stroma of over 90% of malignant epithelial cancers1.

The potential benefit of AVA6000 is that it can deliver doxorubicin, a potent chemotherapeutic agent, directly to the tumor site, while reducing the exposure and toxicity to normal tissues1. Doxorubicin has been one of the most effective and widely used drugs for the treatment of various solid malignancies for over 40 years, but its clinical utility is limited by dose-limiting toxicities, including myelosuppression and cardiotoxicity1.

The success of AVA6000 depends on several factors, such as its safety, efficacy, pharmacokinetics, pharmacodynamics, and marketability. Currently, AVA6000 is in pre-clinical development and has not yet entered human trials2. Therefore, it is too early to predict its likelihood of success with certainty. However, based on the available data and reports, AVA6000 has shown promising results in in vitro and in vivo studies1. It has demonstrated significant anti-tumor activity and increased survival in several animal models with high FAP levels1. It has also shown a high degree of FAP specificity and resistance to hydrolysis by other mammalian peptidases1.

Therefore, AVA6000 seems to have a strong scientific rationale and a unique mechanism of action that could potentially offer a novel and effective treatment option for patients with various types of cancer. However, more research and clinical trials are needed to confirm its safety and efficacy in humans and to compare it with existing therapies. The development of AVA6000 is still in its early stages and there are many challenges and uncertainties ahead. Therefore, I cannot give you a definitive answer to your question, but I hope this information helps you understand more about this innovative drug. 😊

I like your ambitious thinking, Timster. Who d'ya see us targeting in our "multi billion pound take over"?

;-)

Who's to say they won't release other news before the results anno?

Presumably the previous one when they submitted their post. The SP has since risen.

Predators or creditors? :)

Don't count on it as this is Aim and the MMs ain't stupid. They'll be fully aware of those thinking along your lines and will not therefore be looking to fill your pockets through their own predictability. The worrying thing here is how three large customers all backed-off all at the same time. Makes me wonder if a problem relating to the product became evident. Do not be surprised if this drops further tomorrow though.

Good point, PL75 :) I was just keen to restore the intellectual standards of this board - but either way the guy's still a tw@.

I am not invested here, Ianbt, but as a long standing observer of this board I can say that jive_turkey is and continues to be one of the most knowledgeable and constructive posters on here. Your latest post suggests to me that you are a polar opposite who belongs in the school playground. The irony of you calling someone else moronic will not be lost on others who read your post.

There are a lot of good people on this board who've been here for a fair while, those who offer contrarian views within some of the conversations which have taken place included. This share doesn't fall within my current investment criteria but I keep an eye on it and really hope that it continues to come good for the patients, the characters and posters here who've shared so much valuable researcher over the years. Whatever happens, the entertainment value has been top drawer and my gut feeling tells me that good news is pretty close now.

Fairly large spread